Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice

Abstract

Doxorubicin a photosensitive antibiotic is frequently used to treat various malignancies in clinics; however, doxorubicin is also taken up by the normal cells of the body leading to increased oxidative stress and subsequently DNA damage and dysfunction in the cells. The agents which can reduce the adverse effect of doxorubicin will be of great value. The present study has attempted to study the effect of naringin a citrus flavonoid on the doxorubicin-induced oxidative stress in mice liver. The mice were administered with 0, 1, 5 or 10 mg/kg body weight of doxorubicin and treated with 10 mg/kg body weight of naringin before or after doxorubicin treatment. The glutathione concentration and lipid peroxidation and activities of glutathione-s-transferase, catalase and superoxide dismutase were studied at 0.5, 1, 2 and 4 h post-treatment in the mouse liver. The doxorubicin increased the lipid peroxidation in a dose dependent manner at all the post treatment times. Conversely, it attenuated the activities of glutathione-s-transferase, catalase and superoxide dismutase in dose dependent fashion and time dependent manner. A similar effect was observed for glutathione concentration. Treatment of mice with naringin before or after doxorubicin treatment elevated all the antioxidants and reduced the doxorubicin induced lipid peroxidation. The effect of naringin pretreatment was more effective when compared to its post treatment. The naringin was very effective in reducing the oxidative stress induced by doxorubicin as indicated by the elevated levels of glutathione concentration, glutathione-s-transferase, catalase and superoxide dismutase. The pretreatment of naringin was better than its post treatment.

Keywords: Naringin; Doxorubicin; Mice; Glutathione; Catalase; Lipid peroxidation

Introduction

Doxorubicin (also known as Adriamycin) is a cytotoxic photosensitive antibiotic, which was isolated from cultures of soil bacteria Streptomyces peucetius var. Caesius [1]. It belongs to anthracycline group of chemicals that include doxorubicin, daunorubicin, epirubicin, and idarubicin. The anthracyclines are a class of chemotherapeutic agents which are highly active against numerous malignant disorders. The doxorubicin acts on the neoplastic cells during specific phase of the cell cycle, particularly the cells which are in the S phase of the cell division are highly sensitive to its effect [2]. Doxorubicin has been the part of highly effective chemotherapeutic regimens for more than 30 years for the treatment of a wide variety of cancers including bladder, breast, lung, stomach, and ovarian cancers, Hodgkin’s and non-Hodgkin’s lymphomas, certain types of leukemias, multiple myelomas, gastric and thyroid carcinomas, soft tissue sarcomas, osteosarcoma, neuroblastoma, nephroblastoma, Kaposi’s sarcoma and Wilms tumour [3]. The clinical success of doxorubicin is usually limited due to the development of many adverse side effects including myelosuppression, nausea, vomiting, mouth ulcers, local aggressivity, alopecia, hallucinations, vertigo, dizziness, bone marrow aplasia and life threatening cardiotoxicity [4]. Doxorubicin treatment causes hypersensitivity (fever, chills, and urticaria), hyperpigmentation of the nails, lacrimation and conjunctivitis [5]. Doxorubicin also causes immune suppression due to the severe toxic effects on immune cells; as a result the patient becomes more susceptible to microbial infections, fatigue, reduced healing time and gingival bleeding [6].

Anthracyclines kills cancerous cells by triggering the formation of reactive oxygen species (ROS), such as H$_2$O$_2$ and superoxide anion radical, which are generated through redox cycling of DOX in vivo [7,8]. Superoxide radicals may react with hydrogen peroxide to form highly reactive hydroxyl radicals via the iron catalyzed Haber-Weiss reaction. The secondarily derived hydroxyl radicals can cause protein and DNA damage and initiate lipid peroxidation [9], which lead to cytotoxic effects on cells and tissues. The cytotoxic effect of doxorubicin on malignant cells and its toxic effects on various organs are also due to nucleotide base intercalation and cell membrane lipid binding activities [10]. The intercalation of doxorubicin into DNA inhibits nucleotide replication and action of DNA and RNA polymerases. Further, the interaction of doxorubicin with topoisomerase II inhibits the formation of DNA-cleavable complexes inhibiting the relegation of DNA, which is fundamental to DNA replication and it appears
to be an important mechanism of its cytotoxic activity [11,12]. The reductive conversion of doxorubicin has been implicated as a major determinant of doxorubicin cytotoxicity and has been proposed as an underlying factor controlling drug resistance in cancer cells [13,14]. Reductive conversion of doxorubicin is characterized by the one-electron reduction of the quinone moiety of doxorubicin, via NADPH and the cytochrome P450 reductase to a semiquinone radical, which exerts the toxic effect or it can be oxidized back to the quinine form [15]. The ability of doxorubicin to undergo the reductive conversion depends on the availability of molecular oxygen and NADPH, and the activities of several intracellular enzymes such as superoxide dismutase (SOD), glutathione peroxidase, NADPH oxidases (NOXs) and thioredoxin [16].

The antineoplastic drugs are not specifically selective to neoplastic cells and they are also assimilated by normal healthy cells, especially the proliferating ones. This causes major toxicity to various normal organs including heart, liver, kidney, brain bone marrow etc. The cells responsible for triggering many of the body’s crucial immune responses are also affected, depressing the patient’s immune system and increasing the risk of developing viral or bacterial infections [17]. Therefore, any strategy that can reduce the generation of ROS by doxorubicin will be of great importance clinically as it may be able to contain the doxorubicin-induced toxic side effect on different organs. The screening of natural products may provide a major avenue to reduce the doxorubicin-induced toxicity.

Plant produce several secondary metabolites and flavonoids are in particular a large class of poly-phenolic compounds characterized by a common benzo interim protein structure, which are abundantly present in the fruits and vegetables that are regularly consumed by humans. The major sources are apples, citrus fruits, onions, mulberries, bilberries, and beverages such as tea, beer, and wine [18]. Flavonoids include flavones, flavanonols, is-flavones, and the 2,3-dihydroderivatives of flavones, namely flavones [19]. Flavanones, such as hesperidin and naringin, have a more restricted distribution than other flavonoids. They are specifically synthesized by citrus fruits [20]. Naringin (4',5,7-trihydroxyflavanone-7-rhamnoglucoside), aglycone of naringenin is the predominant flavanone synthesized by grapefruit (Citrus paradisi) and is responsible for the bitter taste of grapefruit juices [21]. Naringin (NIN) was first discovered by De Vry in the flowers of grape fruit trees growing in Java in 1857. The name naringin is probably derived from the Sanskrit term “naranji” meaning “orange”. It is present in grapefruit juice up to concentrations of 800 mg/L [22]. Depending up on the maturity of the fruit and the method of purification, naringin naturally occurs as a mixture of chiral isomers that markedly vary in proportion [23]. It is also transformed by the intestinal microflora into many kinds of polyphenolic acids due to ring fission [24,25]. The hydrolysis of naringin results into naringenin in the intestine and is catalyzed by enzymes including α-rhamnosidases and β-glucosidases [26,27]. Naringin interacts with the activities of transporters and enzymatic proteins in the intestine and hence, with the absorption and breakdown of certain drugs, results in altered blood levels [28].

Naringin has also been found to be antiviral, anti-cancer, hepatoprotective, cardioprotective and neuroprotective [29-33]. It is also reported to have antioxidant effects from the study of the inhibition of lipid peroxidation in blood cell membranes and free radical scavenging [34,35]. It inhibits dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes, and might have cancer chemoprevention properties [36,37]. It also protects against radiation and doxorubicin induced chromosomal damage in mouse bone marrow cells [35,38,39]. It has been found to be anti-inflammatory, anti-diabetic, anti-fibrotic, anti-steatorrheic, antidyslipidemic and protected against lipodystrophy and iron induced toxicity [40-44]. Naringin may also have protective effects on cognition and oxidative damage [45]. Naringin reduced cell viability and cell proliferation by arresting the cell cycle at the G1 phase in 5637 cells and inhibited cyclin D1/CDK4 and cyclin E-CDK2 complexes by the increased expression of p21WAF1 and activation of Ras/Raf/ERK [46]. Looking into all these activities of naringin the present study was envisaged to evaluate the effect of naringin on the doxorubicin-induced oxidative stress in the liver of mice.

Materials and Methods

Chemicals and reagents

Naringin and doxorubicin hydrochloride were procured from Acros Organics Ltd., Geel (Belgium), and Getwell Pharmaceuticals, Gurgaon, India, respectively. 1-chloro-2,4- dipinyl- benzene (CDNB), 5,5-dithiobis (2-nitrobenzoic acid) (DTNB), diethylenetriamino-pentaacetic acid (DETPAC) ethylenediaminetetraacetic acid (EDTA), glutathione, nitroblue tetrazolium (NBT), phenazine methosulphate, sodium azide, 2-thio-barbituric acid (TBA), sodium dodecyl sulphate, nicotinamide adenine dinucleotide (NADH), nitroblue tetrazolium, nicotinamide adenine dinucleotide phosphate (NAPDH) tetraethoxypropane, and 5-thio-[2-nitrobenzoic acid]) (TNB) were purchased from Sigma Chemicals Co. St. Louis, USA. Other routine chemicals were procured from Merck India, Mumbai.

Animals care and handling

The animal care and handling were performed according to the guidelines of INSA (Indian National Science Academy, New Delhi, India) and the World Health Organization, Geneva, Switzerland. Usually male Swiss albino mice of eight to ten weeks age and weighing 25-30 g were selected from an inbred colony that was maintained under the controlled conditions of light (12 h light and dark, respectively), temperature (23±2°C), and humidity (50±5%). The animals were given sterile food and water ad libitum throughout the entire study. The four animals were housed in a polypropylene cage consisting sterile paddy husk as the bedding material throughout the experiment. The institutional animal Ethics Committee, of the Mizoram University Aizawl, India had approved the study.

Preparation of the drug

Naringin or doxorubicin was freshly dissolved in sterile double distilled water (DDW) immediately before administration.
Mode of administration

The animals were injected with naringin (NIN) or doxorubicin (DOX) intraperitoneally.

Experimental

The effect of naringin pre and post treatment was determined by dividing the animals into the following groups:

A. DOX group: This group of animals was injected intraperitoneally with 0, 1, 5 or 10 mg/kg b.wt. of doxorubicin alone.

B. NIN+DOX: The animals of this group were administered intraperitoneally with 10 mg/kg b.wt. naringin one hour before administration of 0, 1, 5 or 10 mg/kg b.wt. doxorubicin [39].

C. DOX+NIN: This group of animals was injected intraperitoneally with 10 mg/kg b.wt. naringin one hour after the administration of 0, 1, 5 or 10 mg/kg b.wt. doxorubicin.

Preparation of homogenate

The animals of all groups were killed by cervical dislocation at 0.5, 1, 2 and 4 h post-treatment and their abdominal cavities were opened with the help of scissors and forceps. The livers were perfused with isotonic cold saline transcardially, removed, blot dried, weighed and the 10% homogenate was prepared with PBS.

Total Proteins

The total proteins were estimated by the modified method of Lowry’s [47].

Glutathione

The estimation of glutathione (GSH) contents were performed by earlier described method [48] with minor modifications. Briefly, the proteins were precipitated with 0.5 ml ice cold 10% 5-sulfosalicylic acid and the tubes were incubated on ice for 10 min, centrifuged (Sorvall Instruments RC5C, DuPont, Minnesota, USA) for 15 min at 15,000 rpm in cold (4°C). The protein free supernatant was collected and immediately mixed with 0.5 ml of NADPH (4 mg of reduced form was dissolved in 100 ml of 0.5% NaHCO₃), 0.5 ml of glutathione reductase (6 units/ml in 0.1 M phosphate buffer, pH 7.0) and 1 ml of 0.6 M DTNB [prepared in 0.2 M phosphate buffer (pH 8)]. The formation of TNB was read against the blank in a UV-Visible double beam spectrophotometer (Shimadzu Corporation, Tokyo, Japan) at 412 nm. A sample lacking GSH was used as a blank. The GSH concentration has been expressed as µmol/mg protein. Standard curve was plotted using different concentrations of GSH.

Glutathione-S-Transferase

The protocol described by Habig et al. [49] was used to measure the activity of glutathione-S-transferase (GST), where the homogenate was mixed with 0.1 M potassium phosphate buffer, CDNB and 10 mM GSH, and kept in water bath for 10 min at 37°C. The absorbance was recorded at 1 min intervals against the blank at 340 nm using a UV-VIS spectrophotometer. The GST activity has been expressed as nmol/mg of protein.

GST activity = Absorbance of sample - Absorbance of blank × 1000/9.6 × Vol of sample

Catalase

The catalytic reduction of hydrogen peroxide was used to measure the catalase activity [50], where, hydrogen peroxide was added to the tissue homogenate and the mixture was incubated at 37°C. The hydrogen peroxide decomposition was monitored at 0.5 s, 10 s intervals up to 30 s and the absorbance was read against the blank at 240 nm using a UV-VIS spectrophotometer. The average difference in absorbance in 30 s was calculated.

Superoxide dismutase

The activity of superoxide dismutase (SOD) was determined as described earlier [51]. Briefly, the homogenate was mixed with phenazine methosulphate, nitroblue tetrazolium and NADH and incubated at 30°C for 90 sec. The reaction was terminated by the addition of acetic acid and n-butanol. Blank was prepared in a similar fashion without the sample and the reaction was stopped by adding acetic acid and n-butanol. The sample absorbance was read against the blank at 560 nm in a UV-VIS spectrophotometer.

Lipid peroxidation

The induction of lipid peroxidation (LOO) was measured as various thiobarbituric acid reactive substances (TBARS) including malondialdehyde, lipid hydroperoxides and aldehydes in the homogenate [52]. The liver homogenate was heated with thiobarbituric acid (0.8%), sodium dodecyl sulphate (0.1%) and acetic acid (20%) in a boiling water bath for 30 min lipoproteins are precipitated. The resultant mixture was cooled, extracted with n-butanol-pyridine, and the absorbance of the butanol layer was recorded at 532 nm using UV-Visible double beam spectrophotometer. The resultant concentration of TBA reactive substances is expressed as nmol/mg protein obtained from a standard curve of tetraethoxypropane.

Statistical Analyses

The statistical significance among all the treatments was determined by Students “t” test and analysis of variance (ANOVA). The results are the average of three individual experiments. The test of homogeneity was applied and since the data of each experiment did not differ significantly from one another and hence, all the data are combined and means calculated. A p value of < 0.05 was considered statistically significant.

Results

The results are expressed as mean±SEM (standard error of the mean) in Table 1-5 and Figure 1-10.

Glutathione

The normal GSH concentration in the non-drug treated control Swiss albino liver has been 13.5±2.43 µmol/mg protein (Table 1). Administration of naringin alone did not significantly change the
GSH concentration when compared to control (data not shown). Treatment of mice with different concentrations of doxorubicin led to a dose dependent depletion in the GSH concentration and a greatest attenuation was observed for 10 mg/kg b. wt. DOX (Figure 1 & 2). The assay of GSH revealed a time dependent elevation in the GSH contents that was lowest at 1/2 h post-treatment and continued to elevate until 4 h post-treatment without restoration to normal level (Figure 1). Naringin treatment before 1 h of DOX treatment caused a significant rise in the GSH concentration as early as 0.5 h post treatment, which steadily rose up to 4 h post-treatment where the GSH concentration was the maximum (Figure 2). Despite this the rise in GSH contents depended on the DOX dose; higher the DOX dose lesser was the increase (Table 1). Treatment of animals with naringin after DOX treatment led to an increase in the GSH concentration in the mouse liver at all DOX doses; however, this elevation was not significantly higher when compared to the DOX treatment alone at 0.5 and 1 h post-treatment however, it was significantly higher at 2 and 4 h post-treatment (Table 1). The effect of naringin pretreatment had a greater effect than the post treatment (Table 1, Figures 1 & 2).

Table 1: Alteration in the glutathione concentration in the liver of mice treated with different doses of doxorubicin before and after naringin treatment at various post treatment times.

| Treatment Group | Dose (mg/kg b.wt.) | Post Treatment Times (h) |
|-----------------|--------------------|--------------------------|
|                 | 0.5    | 1      | 2      | 4      |
| Control         | 0      | 13.5±2.43 | 13.5±2.43 | 13.5±2.43 |
| DOX             | 1      | 7.92±0.19$†$ | 8.60±0.31$†$ | 9.23±0.55$†$ | 9.58±0.19$†$ |
|                 | 5      | 4.40±0.13$‡$ | 4.64±0.29$‡$ | 5.20±0.13$‡$ | 5.58±0.13$‡$ |
| NIN+DOX         | 1      | 9.59±0.14$*#$ | 10.29±0.31$*#$ | 10.93±0.56$*#$ | 11.29±0.20$*#$ |
|                 | 5      | 6.91±0.20$*#$ | 7.55±0.29$*#$ | 8.35±0.26$*#$ | 8.50±0.24$*#$ |
| DOX+NIN         | 1      | 8.50±0.14 | 9.19±0.31 | 9.81±0.55$‡$ | 10.17±0.19$‡$ |
|                 | 5      | 6.27±0.20 | 6.91±0.29 | 7.71±0.26$‡$ | 7.86±0.24$‡$ |
|                 | 10     | 4.59±0.13 | 5.18±0.18 | 5.55±0.26$‡$ | 5.28±0.14 |

p<0.05, No symbol: Non-significant
$†$: Statistical significance was calculated against control with the positive control DOX treatment alone.
*#: Statistical significance was calculated against DOX alone treatment in their respective treatment hours.
$‡$: Statistical significance was calculated against DOX+NIN combination treatment in their respective treatment hours.
$†$: Statistical significance was calculated against their corresponding 0.5 h treatment combinations.

Glutathione-S-transferase

The GST activity in the liver of non-drug treated control mice was 11.85±1.10 nmol/mg protein (Table 2) and naringin treatment alone did not alter the glutathione-S-transferase activity significantly in comparison with the control (data not shown). Treatment of mice with different doses of DOX reduced GST activity significantly at all the post treatment times (Figure 3). There has been a 2.8, 3.3 and 5 fold reduction in the catalase activity in the livers of mice treated with 1, 5 and 10 mg/kg DOX, respectively (Table 2). The GST activity depleted steadily with time and it was lowest at 4 hours post-treatment (Figure 4). Treatment of naringin before and after DOX administration resulted in an elevation in the GST activity (Figure 3), which depended on the assay time and DOX dose (Table 2). This elevation in the GST activity was significantly higher than the DOX treatment alone at 1, 2 and 4h post treatment (Table 2). The rise in the GST activity was greater in the naringin pretreated group than the post-treated group (Figures 3 & 4).

Catalase

The liver of normal untreated mice showed 43.50 nmol/mg protein catalase activity (Table 3) which did not change after naringin administration (data not shown). The administration of mice with different doses of DOX decreased the catalase activity in dose dependent manner (Figure 5) and the greatest reduction in the catalase activity was observed for the 10 mg/kg DOX, where it was more than three folds (Table 3 & Figure 5). The catalase activity also declined in a time dependent manner after DOX treatment and the lowest activity was observed at 4 h post treatment (Figure 6). Despite the signs of recovery the catalase activity was far from normal (Figure 6). This reduction in catalase activity by DOX was 3, 3.4 and 4 folds at 4 h post treatment for 1, 5 and 10 mg/kg DOX, respectively (Table 3). The treatment of mice with 10 mg/kg b. wt. of naringin before DOX administration resulted in a significant rise in the catalase activity at all the assay times and it was higher at 0.5 h post DOX treatment than the other assay times (Table 3). Administration of mice with naringin after DOX treatment also significantly increased the catalase activity in the mouse liver depending on the DOX dose and assay time (Table 3) and maximum elevation was observed at 0.5 h post-treatment (Figure 6). Thereafter catalase activity steadily declined until 4 h post-treatment (Figure 6).
Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice

Figure 1: Alteration in the doxorubicin-induced decline in glutathione (GSH) concentration in mouse liver treated with 10mg/kg b.wt. naringin at different post-treatment times. Upper left: 0.5h; Upper right: 1h; Lower left: 2h and Lower right: 4h post-treatment. Squares: Doxorubicin; Circles: Naringin + Doxorubicin and Triangles: Doxorubicin + Naringin.

Figure 2: Alteration in the doxorubicin-induced decline in glutathione (GSH) concentration by 10mg/kg b.wt. naringin in mouse liver with assay time. a) Doxorubicin; b) Naringin + Doxorubicin; and c) Doxorubicin + Naringin. Circles: 1 mg Doxorubicin; and Triangles: 5 mg Doxorubicin Squares: 10 mg Doxorubicin.

Figure 3: Alteration in the doxorubicin-induced decline in glutathione-s-transferase (GST) activity by naringin (10mg/kg b.wt) in mouse liver at different post-treatment times. Upper left: 0.5h; Upper right: 1h; Lower left: 2h and Lower right: 4h post-treatment. Squares: Doxorubicin; Circles: Naringin + Doxorubicin and Triangles: Doxorubicin + Naringin.

Figure 4: Alteration in the doxorubicin-induced glutathione-s-transferase (GST) activity with time in mouse liver administered with 10mg/kg b.wt. naringin. a) Doxorubicin; b) Naringin + Doxorubicin; and c) Doxorubicin + Naringin. Circles: 1 mg Doxorubicin; and Triangles: 5 mg Doxorubicin Squares: 10 mg Doxorubicin.
Table 2: Alteration in the glutathione-s-transferase activity in the liver (nmol/mg protein) of mice treated with different doses of doxorubicin before and after naringin treatment at various post treatment times.

| Treatment Group | Dose (mg/kg b.wt.) | Post Treatment Times (h) |
|-----------------|--------------------|-------------------------|
|                 |                    | 0.5                     | 1               | 2               | 4               |
| Control         | 0                  | 11.85±1.10              | 11.85±1.10      | 11.85±1.10      | 11.85±1.10      |
|                 | 1                  | 4.25±0.59†              | 3.19±0.15†      | 2.78±0.11†      | 2.43±0.25†      |
|                 | 5                  | 3.60±0.40‡              | 2.60±0.13†      | 2.36±0.09†      | 2.31±0.21†      |
|                 | 10                 | 2.30±0.19‡              | 2.34±0.22‡      | 1.83±0.13‡      | 1.58±0.08‡      |
| DOX             | 1                  | 4.94±0.38               | 3.76±0.15†      | 3.57±0.05*†     | 3.28±0.38*†     |
|                 | 5                  | 3.74±0.27               | 3.21±0.16       | 2.98±0.13†      | 3.08±0.25*      |
|                 | 10                 | 2.93±0.13               | 2.99±0.08       | 2.52±0.10       | 2.16±0.04       |
| DOX+NIN         | 1                  | 4.65±0.07               | 4.29±0.16*      | 3.77±0.03*†     | 3.62±0.07*†     |
|                 | 5                  | 3.87±0.04               | 3.77±0.024*     | 3.54±0.10*      | 3.41±0.09*      |
|                 | 10                 | 3.45±0.01*#             | 3.18±0.021*     | 2.87±0.008†     | 2.58±0.03†      |
| NIN+DOX         | 1                  | 23.24±0.17*#            | 21.61±2.17*#†   | 22.24±1.59*#†   | 19.83±0.70*#†   |
|                 | 5                  | 19.45±0.49#             | 18.17±2.17*#†   | 19.31±1.31*#†   | 16.12±0.74*#†   |
|                 | 10                 | 16.03±0.11*#            | 16.91±0.91*#    | 16.06±1.43*#†   | 15.29±0.69*#†   |
| DOX+NIN         | 1                  | 22.24±2.16*             | 19.54±0.18†     | 20.30±1.20†     | 17.55±2.62†     |
|                 | 5                  | 19.08±1.04*             | 15.82±1.41†     | 15.50±0.99†     | 14.20±0.73†     |
|                 | 10                 | 14.25±1.20*             | 13.76±0.30†     | 13.17±1.76†     | 13.09±1.50†     |

p<0.05, No symbol: Non-significant
‡: Statistical significance was calculated against control with the positive control i.e DOX treatment alone.
*: Statistical significance was calculated against DOX alone treatment in their respective treatment hours.
#: Statistical significance was calculated against DOX+NIN combination treatment in their respective treatment hours.
†: Statistical significance was calculated against their corresponding 0.5h treatment combinations.

Table 3: Alteration in the catalase activity in the liver of mice treated with different doses of doxorubicin before and after naringin treatment various post treatment times.

| Treatment Group | Dose (mg/kg b.wt.) | Post Treatment Times (h) |
|-----------------|--------------------|-------------------------|
|                 |                    | 0.5                     | 1               | 2               | 4               |
| Control         | 0                  | 43.50±3.70              | 43.50±3.70      | 43.50±3.70      | 43.50±3.70      |
|                 | 1                  | 19.51±1.22‡             | 17.50±0.31‡†    | 16.71±0.88‡†    | 14.02±1.89‡†    |
|                 | 5                  | 16.36±1.20‡             | 15.95±0.97‡†    | 15.37±0.46‡†    | 12.93±2.44‡†    |
|                 | 10                 | 12.88±0.43‡             | 13.93±1.51‡†    | 12.36±0.25‡†    | 10.76±1.44‡†    |
| DOX             | 1                  | 23.24±0.17*#            | 21.61±2.17*#†   | 22.24±1.59*#†   | 19.83±0.70*#†   |
|                 | 5                  | 19.45±0.49‡             | 18.17±2.17*#†   | 19.31±1.31*#†   | 16.12±0.74*#†   |
|                 | 10                 | 16.03±0.11*#            | 16.91±0.91*#    | 16.06±1.43*#†   | 15.29±0.69*#†   |
| NIN+DOX         | 1                  | 22.24±2.16*             | 19.54±0.18†     | 20.30±1.20†     | 17.55±2.62†     |
|                 | 5                  | 19.08±1.04*             | 15.82±1.41†     | 15.50±0.99†     | 14.20±0.73†     |
|                 | 10                 | 14.25±1.20*             | 13.76±0.30†     | 13.17±1.76†     | 13.09±1.50†     |

p<0.05, No symbol: Non-significant
‡: Statistical significance was calculated against control with the positive control i.e DOX treatment alone.
*: Statistical significance was calculated against DOX alone treatment in their respective treatment hours.
#: Statistical significance was calculated against DOX+NIN combination treatment in their respective treatment hours.
†: Statistical significance was calculated against their corresponding 0.5h treatment combinations.
Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice

Figure 5: Alteration in the doxorubicin -induced decline in catalase activity in mouse liver by 10mg/kg b.wt. naringin at different post-treatment times. Upper left: 0.5h; Upper right: 1h; Lower left: 2h and Lower right: 4h post-treatment. Squares: Doxorubicin; Circles: Naringin + Doxorubicin and Triangles: Doxorubicin + Naringin.

Figure 6: Alteration in the doxorubicin -induced catalase activity with time in mouse liver administered with 10mg/kg b.wt. naringin. a) Doxorubicin; b) Naringin + Doxorubicin; and c) Doxorubicin + Naringin. Circles: 1 mg Doxorubicin; and Triangles: 5 mg Doxorubicin Squares: 10 mg Doxorubicin.

Figure 7: Alteration in the doxorubicin -induced decline in superoxide dismutase activity by 10mg/kg b.wt. naringin in mouse liver at different post treatment times. Upper left: 0.5h; Upper right: 1h; Lower left: 2h and Lower right: 4h post-treatment. Squares: Doxorubicin; Circles: Naringin + Doxorubicin and Triangles: Doxorubicin + Naringin.

Figure 8: Alteration in the doxorubicin -induced superoxide dismutase activity with time in mouse liver administered with 10mg/kg b.wt. naringin(a) Doxorubicin; b) Naringin + Doxorubicin; and c) Doxorubicin + Naringin. Circles: 1 mg Doxorubicin; and Triangles: 5 mg Doxorubicin Squares: 10 mg Doxorubicin.

Citation: Jagetia GC, Lalrinengi C (2017) Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice. MOJ Anat & Physiol 4(2): 00130. DOI: 10.15406/mojap.2017.04.00130
Superoxide dismutase

The SOD activity in the normal untreated mice liver has been 7.12±11 nmol/protein (Table 4) and naringin treatment did not have any significant effect on normal SOD activity (data not shown). Treatment of mice with different doses of doxorubicin caused a dose dependent reduction in the SOD activity at all post-treatment assay times and it was significantly lower than the control (Table 4 & Figure 7). The SOD activity reached its lowest level after administration of 10 mg/kg DOX, which was almost two fold lower at all post-treatment assay times (Table 4). The SOD activity declined continuously with time until 4 h post-treatment where it was lowest (Figure 8). Naringin treatment before DOX administration did not alter the pattern of decline in the SOD activity in naringin+DOX group, except that the SOD activity was significantly enhanced (Figure 7 & 8). The SOD activity was 2 fold greater at 0.5 h, whereas this elevation was approximately 3.5 fold at 1 and 2 h post-DOX-treatment, respectively (Table 1). Administration of 10 mg/kg b. wt. of naringin before DOX treatment led to a significant rise in the SOD activity at all post treatment times, except for 5 mg at 0.5 h where this increase was non-significant (Table 4). At lower DOX doses the elevation was greater when compared to the higher dose of DOX (Figure 8). The treatment of naringin after DOX administration also increased the SOD activity at all post treatment assay times; however significant increases were recorded only for 1, 2 and 4 h post treatment for 1 mg/kg DOX (Table 4).

Table 4: Alteration in the superoxide dismutase activity in the liver of mice treated with different doses of doxorubicin before and after naringin treatment at various post treatment times.

| Treatment Group | Dose (mg/kg b.wt.) | Post Treatment Times (h) | 0.5       | 1        | 2        | 4        |
|-----------------|--------------------|--------------------------|-----------|----------|----------|----------|
|                 |                    |                          | Control   | DOX      | NIN+DOX  | DOX+NIN  |
| Control         | 0                  |                          | 7.21±0.11 | 7.21±0.11| 7.21±0.11| 7.21±0.11|
| DOX             | 1                  |                          | 5.01±0.16 | 4.44±0.06 || 3.84±0.16 || 3.54±0.10 ||
|                 | 5                  |                          | 4.69±0.11 | 3.57±0.13 || 3.19±0.20 || 2.78±0.15 ||
|                 | 10                 |                          | 3.66±0.07 | 3.41±0.11 || 2.92±0.10 || 2.52±0.03 ||
| NIN+DOX        | 1                  |                          | 6.18±0.15 | 5.66±0.08 || 5.41±0.03 || 5.21±0.01 ||
|                 | 5                  |                          | 5.31±0.08 | 4.92±0.09 || 4.53±0.13 || 4.25±0.04 ||
|                 | 10                 |                          | 4.77±0.04 | 4.35±0.03 || 4.25±0.04 || 4.10±0.04 ||
| DOX+NIN        | 1                  |                          | 5.84±0.07 | 5.42±0.11 || 5.13±0.05 || 5.10±0.02 ||
|                 | 5                  |                          | 4.73±0.36 | 4.29±0.08 || 3.68±0.21 || 3.44±0.24 ||
|                 | 10                 |                          | 4.21±0.02 | 4.03±0.11 || 3.82±0.03 || 3.14±0.10 ||

p<0.05, No symbol: Non-significant
‡: Statistical significance was calculated against control with the positive control i.e. DOX treatment alone.
*: Statistical significance was calculated against DOX alone treatment in their respective treatment hours.
#: Statistical significance was calculated against DOX+NIN combination treatment in their respective treatment hours.
†: Statistical significance was calculated against their corresponding 0.5h treatment combinations.

Table 5: Alteration in lipid peroxidation (nmol/mg protein) in the liver of mice treated with different doses of doxorubicin before and after naringin treatment at various post treatment times.

| Treatment Group | Dose (mg/kg b.wt.) | Post Treatment Times (h) | 0.5       | 1        | 2        | 4        |
|-----------------|--------------------|--------------------------|-----------|----------|----------|----------|
|                 |                    |                          | Control   | DOX      | NIN+DOX  | DOX+NIN  |
| Control         | 0                  |                          | 0.1±0.005 | 0.1±0.005| 0.1±0.005| 0.1±0.005|
| DOX             | 1                  |                          | 0.18±0.006| 0.17±0.004| 0.19±0.002| 0.19±0.005||
|                 | 5                  |                          | 0.19±0.003| 0.20±0.002| 0.19±0.003| 0.20±0.004||
|                 | 10                 |                          | 0.21±0.007| 0.23±0.003| 0.23±0.005| 0.23±0.003||
| NIN+DOX        | 1                  |                          | 0.15±0.004| 0.15±0.005| 0.15±0.007| 0.15±0.005||
|                 | 5                  |                          | 0.16±0.003| 0.16±0.003| 0.18±0.002| 0.17±0.005||
|                 | 10                 |                          | 0.17±0.002| 0.21±0.003| 0.20±0.005| 0.19±0.002||
| DOX+NIN        | 1                  |                          | 0.15±0.002| 0.16±0.002| 0.16±0.001| 0.16±0.003||
|                 | 5                  |                          | 0.16±0.004| 0.17±0.003| 0.19±0.004| 0.18±0.001||
|                 | 10                 |                          | 0.19±0.004| 0.22±0.004| 0.22±0.004| 0.21±0.004||

p<0.05, No symbol: Non-significant
‡: Statistical significance was calculated against control with the positive control i.e DOX treatment alone.
*: Statistical significance was calculated against DOX alone treatment in their respective treatment hours.
#: Statistical significance was calculated against DOX+NIN combination treatment in their respective treatment hours.
†: Statistical significance was calculated against their corresponding 0.5h treatment combinations.

Citation: Jagetia GC, Lalrinengi C (2017) Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice. MOJ Anat & Physiol 4(2): 00130. DOI: 10.15406/mojap.2017.04.00130
Lipid peroxidation

The spontaneous lipid peroxidation in mouse liver has been 0.01±0.005 nmol/mg protein (Table 5) and naringin administration did not alter this status significantly (data not shown). The administration of different doses of doxorubicin to mice resulted in a dose dependent increase in the lipid peroxidation when compared to the control, and a highest lipid peroxidation was observed for 10 mg/kg DOX (Table 5 & Figure 9). There has not been much variation in the lipid peroxidation with time (Table 5). Administration of naringin before DOX treatment significantly reduced lipid peroxidation at all post treatment assay times (Table 5), whereas administration of naringin after DOX treatment also reduced the lipid peroxidation significantly at 0.5 and 1h when compared to DOX treatment alone (Table 5 & Figure 10).

Discussion

Doxorubicin is a wide spectrum chemotherapeutic drug, which is used to treat several malignancies. However, it produces deleterious effects on several normal tissues that may result in the production of second malignancies in the long term survivors [53]. The induction of secondary neoplasia is a major stumbling block in realizing its full potential in treating various malignant diseases. The doxorubicin acts by intercalating into the cellular DNA and also by inhibiting the enzyme topoisomerase II, which plays a central role during DNA replication [54]. Doxorubicin also acts by producing free radicals that result in the increased oxidative stress in the normal cells [55]. DOX interferes with non-enzymatic metabolic reactions in which iron is involved, and leads to ROS production [56]. Both radical and non-radical ROS have the potential to cause cellular damage leading to tissue toxicity. Therefore present study was undertaken to study the effect of naringin treatment on the DOX-induced oxidative stress.

The use of oxygen for energy production by the aerobic organisms has led to the production of various free radicals and other ROS, as a result, cells developed antioxidant system that is capable of preventing and repairing ROS-mediated damages. The enzymatic antioxidants include, but are not limited to superoxide dismutase, catalase, glutathione-s-transferase, glutathione peroxidase, and peroxiredoxin (Prx). Superoxide dismutase was the first antioxidant enzymes to be discovered [57]. Glutathione (GSH) a tripeptide that contains a sulfhydryl group and an amino acid derivative serves several important functions within the mammalian antioxidant system. GSH is considered to be the most abundant intracellular thiol-based non enzymatic antioxidant, which is considered by some as the cell’s first line of defense against oxidative stress. It cycles between two forms: the reduced thiol form, GSH, and the oxidized form, GSSG and is converted back to reduced form [58-60]. Doxorubicin treatment reduced the GSH concentration in a dose and time dependent manner, whereas treatment of mice with naringin before or after DOX administration elevated it significantly. The naringin pretreatment afforded better protection against DOX induced GSH depletion than the post-treatment. Similarly DOX has been found to reduce GSH level in mice and rat liver and heart earlier.
Naringin treatment has been found to elevate the GSH concentration in the heart and liver of doxorubicin treated mice and rats [32,63-65]. Similarly, extract of *Aegle marmelos* has been reported to elevate myocardial glutathione in mice [62]. Glutamine an amino acid has been reported to protect against the DOX-induced depletion in GSH in rats [61]. The reduction in doxorubicin-induced oxidative stress may be due to its ability to neutralize doxorubicin-induced free radicals and ROS or its ability to participate through other enzymatic reactions [66].

Glutathione-s-transferases or GSTs are a multi gene family of enzymes, which are found in almost all organisms. The main function of GSTs is to catalyze the coupling of GSH with other electrophilic molecules to detoxify the endogenous and exogenous toxicants. It also modulates cell proliferation and cell death [67]. The increased toxicity of DOX may be due to its ability to deplete the GST. The DOX treatment has actually reduced the activity of GST in a dose dependent manner after ad ministration of naringin before and after DOX treatment. The naringin has been reported to elevate the GST activity in mouse heart and liver of mouse and rat earlier [32,63]. This elevation in GST by naringin may play an important role in reduced DOX toxicity in the liver.

The hydrogen peroxide is generated during respiration and DOX also aids in its production. The enzyme catalase is present in all organisms that utilize oxygen for energy generation and it plays a crucial role in neutralizing the hydrogen peroxide, which is a highly oxidizing agent. The catalase acts upon hydrogen peroxide, which is broken down into harmless products such water and molecular oxygen [68]. The DOX treatment has been found to reduce the activity of catalase enzyme in a dose and time dependent manner, whereas naringin pretreatment or post treatment elevated the catalase activity when compared to DOX treatment alone. Similarly, DOX treatment has been found to decrease the catalase activity in mouse and rat heart and liver earlier [32,62,63,65]. The naringin treatment reduced the catalase activity in the mouse liver which is in agreement with the earlier studies where a similar effect has been reported [32,63-65]. Both the treatment of naringin before or after DOX administration was equally effective in raising the catalase activity in mouse liver in the present study. Likewise, *Aegle marmelos* extract attenuated the doxorubicin-induced alleviation in the catalase activity of mice heart [62]. Wheat germ oil and phytic acid prevented the doxorubicin-induced decline in the catalase activity in rat liver, kidney and spleen [69].

The superoxide dismutases are highly conserved and ubiquitously present enzymes in all organisms and their main function is to convert superoxide cation generated during respiration into molecular oxygen and hydrogen peroxide and play important role in detoxification [70]. The DOX treatment reduced the activity of SOD in a dose and time dependent manner and treatment of mice the naringin before or after DOX administration led to an increase in its activity. The naringin pretreatment was more effective than the post treatment. DOX has been reported to decrease the activity of SOD earlier leading to oxidative stress [32,62,63]. Naringin treatment has been reported to inhibit the DOX induced reduction in the SOD activity in heart and liver of mice and rats [32,63-65]. Similarly, naringin also suppressed the belomycin-induced decline in the SOD activity [43]. Phytic acid and wheat germ oil have been found to arrest the doxorubicin-induced decline in SOD activity in rat liver, kidney and spleen [69].

The lipids are integral part of membranes and they are the primary targets of ROS leading to the formation of lipid peroxides [71]. The estimation of lipid peroxidation serves as an indirect marker of oxidative stress. The DOX induced ROS may interact with membrane lipid producing their peroxides [15]. The increased lipid peroxidation by DOX in a concentration dependent manner is due to this activity of DOX. The administration of naringin before and after DOX treatment led to a significant decline in the lipid peroxidation and both treatments were equally effective. DOX treatment has been earlier reported to increase the lipid peroxidation in rat and mice [32,61-65,72]. Naringin treatment has been found to protect mouse and rat liver and heart against the DOX-induced lipid peroxidation [32,63-65]. Naringin has also been reported to protect against iron and belomycin-induced lipid peroxidation in earlier studies [40,41,43]. Similarly L-glutamine has been also reported to protect against the DOX-induced lipid peroxidation [61].

The exact mechanism by which naringin attenuated the DOX-induced oxidative stress is not clearly understood. The naringin may have employed multiple putative mechanisms to alleviate the DOX-induced oxidative stress. The DOX produces free radicals by the activation of NADPH oxidase system and naringin has been reported to inhibit the activation of NADPH oxidase leading to the attrition of free radical formation [73,74]. Our earlier study has also shown that naringin inhibits the generation of free radicals in *vitro* [35], which would have been responsible for elevated activities of GST, catalase and SOD and higher glutathione contents in liver mice receiving naringin before and after DOX treatment. The DOX has been reported to produce greater amount of free radicals when free iron is available and chelation of iron by naringin may be another mechanism of alleviation of DOX-induced oxidative stress, since naringin chelates iron [41]. The naringin supplementation has been reported to upregulate mRNA expression of superoxide dismutase, catalase and glutathione peroxidase genes [75]. The transcriptional activation of NF-κB and COX-II by DOX increases oxidative stress and their transcriptional suppression by naringin may have also reduced the DOX-induced oxidative stress [76-79]. Nrf2 is an important transcriptional factor responsible for the expression of different antioxidant genes and its suppression by DOX may have arrested the increased oxidative causing a decline in all the antioxidants. The presence of naringin may have triggered the activation Nrf2 signalling pathway reducing the DOX induced oxidative stress [80].

**Conclusions**

The DOX induced the oxidative stress in the mouse liver whereas treatment of mice with naringin before or after DOX administration elevated the oxidative stress and reduced lipid peroxidation. The protection against increased DOX-induced oxidative stress in mice liver may be due to the free radical scavenging and iron chelating ability of naringin. The naringin may have also inhibited the transcriptional activation of NF-κB.
COX-II and NADPH oxidase genes coupled with the activation of superoxide dismutase, catalase, glutathione peroxidase and Nrf2 genes responsible for triggering of antioxidant cascade.

Acknowledgements

This work was supported by a grant no. F4-10/2010(BSR) UGC from the University Grants Commission, New Delhi, India.

References

1. Grein A, Spalla C, Canevazzi G, Dimarco A (1963) Descrizione e classificazione di un attimomicete (Streptomyces peucetius sp nova) produttrice di una sostanza e attiva antitumorale: la daunomicina. G Microbiol 11: 109-115.

2. Kusyk CJ, Hsu TC (1976) Adriamycin-induced chromosome damage: elevated frequencies of isochromatid aberrations in G2 and S phases. Experientia 32(12): 1513-1514.

3. Carvalho FS, Burgeime A, Garcia R, Moreno AJ, Carvalho RA, et al. (2014) Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1): 106-135.

4. Káčér R, Adam V, Hrabeta J, Eckschlager T, Smtny S, et al. (2012) Anthracycines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Ther 133(1): 26-39.

5. Mancuso A, Migliorino M, De Santis S, Sampieroni A, De Marinis F (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17(1): 146-150.

6. Chatterjee K, Zhang J, Honbo N, Karlirn JS (2010) Doxorubicin cardiomyopathy. Cardioiology 115(2): 155-162.

7. Olsén RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4(13): 3076-3086.

8. Šimůnek T, Štěrba M, Popelová O, Adamcová M, Hrdina R, et al. (2009) Anthraccline-induced cardiotoxicity: overview of studies examining the role of oxidative stress and free cellular iron. Pharmacol Rep 61(1): 154-171.

9. Hallwell B, Gutteridge JMC (1989) Free Radicals in Biology and Medicine. (2nd edn). Oxford University Press, New York, USA, pp. 543.

10. Box VG (2007) The intercalation of DNA double helices with doxorubicin and nagalominic. J Mol Graph Model 26(1): 14-19.

11. Tawney KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673): 466-486.

12. Yang ES, Huh VJ, Park JW (2013) RNA interference targeting sensitive-to-apoptosis gene potentiates doxorubicin- and staurosporine induced apoptosis of PC3 cells. Anticancer Res 33(3): 847-855.

13. Sinha BK, Minnaghaug EG, Rajagopal S, Myers CE (1989) Adriamycin activation and oxygen free radical formation in human breast tumor cells:Protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49(14): 3844-3848.

14. Kostrzewska Nowak D, Paine MJ, Wolf CR, Tansuik J (2005) The role of bioreductive activation of doxorubicin in cytotoxic activity against leukemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer 93(1): 89-97.

15. Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012: 645460.

16. Doroshow JH, Alman S, Esworthy S, Chu FF, Burke T (1991) Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radic Res Commun 12-13(2): 779-781.

17. Shephard GM (2003) Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24(3): 253-262.

18. Hertog MGL, Kromhout D, Aravanis C, Blackburn H, Buzina R, et al. (1995) Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155(4): 381-386.

19. Tripoli E, La Guardia M, Giammanco S, Di Majo D, Giammanco M (2007) Citrus flavonoids: molecular structure, biological activity and nutritional properties: A review. Food Chem 104(2): 466-479.

20. Benavente García O, CastBilo, Marin FR, Ortono A, Del Rio JA (1997) Uses and properties of citrus flavonoids. J Agric Food Chem 45(12): 4505-4515.

21. Ortono A, Garcia Puig D, Fuster MD, Perez ML, Sabater F, et al. (1995) Flavanone and norkatokeleit in different varieties of grapefruit and pummelo. J Agric Food Chem 43: 1-5.

22. Zhang J (2007) Flavonoid in grape fruit and commercially grape fruit juices: concentration, distribution, and potential health benefits. Proc Fla State Hort Soc 120: 288-294.

23. Wilcox L, Borradale M, Murray WH (1999) Antithgerogenic properties of naringenin, a citrus flavonoid. Cardiovasc Drug Rev 17(2): 160-179.

24. Kim DH, Jung EA, Sohng IS, Han JA, Kim TH, et al. (1998) Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm Res 21(1): 17-23.

25. Kanaze FI, Bounartzi ML, Georgarakis M, Niopas I (2007) Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutri 61(4): 472-477.

26. Wang MJ, Chao PD, Hou YC, Hsiu SL, Wen KC, et al. (2006) Pharmacokinetics and conjugation metabolism of naringin and naringin in rats after single dose and multiple dose administrations. J Food Drug Anal 14: 247-253.

27. Liu Y, Wu H, Nie YC, Chen JL, Su WW, et al. (2011) Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Int Immunopharmacol 11(10): 1606-1612.

28. Shirasaki Y, Suzuki K, Shichiri M, Nakanishi T, Tama I (2011) Intestinal absorption of hmg-coa reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and p-glycoprotein/multidrug resistance. Drug Metab Pharmacokinet 26(2): 171-179.

29. Gammal AA, Mansour RM (1986) Antimicrobial activities of some flavonoid compounds. Zentrabl Mikrobiol 141(7): 361-365.

30. Aboobaker VS, Balgi AD, Bhattacharya RK (1997) Flavonoids and naringenin in rats after single dose and multiple dose administrations. J Food Drug Anal 14: 247-253.
31. Gordon PB, Holen I, Seglen PO (1995) Protection by naringin and some other flavonoids of hepatic cytochrome P-450 and endoplasmic reticulum against inhibition by okadaic acid. J Biol Chem 270(11):5830-5838.

32. Jagetia GC, Reddy TK (2014) The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity. J Mol Chem 3(1).

33. Kim HD, Jeong KH, Jung UJ, Kim SR (2016) Naringin treatment induces neuroprotective effects in a mouse model of Parkinson’s disease in vivo, but not enough to restore the lesioned dopamineergic system. J Nutr Biochem 28:140-146.

34. Affrey A, Salvayre R, Douste Blazy L (1987) Comparison of the protective effect of various flavonoids against lipid peroxidation of erythrocyte membranes (induced by cumene hydroperoxide). Fundam Clin Pharmacol 1(6):451-457.

35. Jagetia GC, Venkatesha VA, Reddy TK (2003) Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. Mutagenesis 18(4):337-343.

36. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3(4):363-371.

37. Jagetia GC, Reddy TK (2004) Chemopreventive effect of naringin on the benzo[a]pyrene-induced forestomach carcinoma in mice. International Journal of Cancer Prevention 1(6):429-444.

38. Jagetia GC, Reddy TK (2002) The grapefruit flavonone naringin protects against the radiation-induced genomic instability in the mice bone marrow: a micronucleus study. Mutat Res 519(1-2):37-48.

39. Jagetia GC, Reddy TK (2016) The grape fruit flavonoid naringin protects against the doxorubicin-induced micronuclei formation in mouse bone marrow. Int J Mol Biol 1(1):00006.

40. Jagetia GC, Reddy TK, Venkatesha VA, Kedlaya R (2004) Influence of naringin on ferric iron induced oxidative damage in vitro. Clin Chim Acta 347(1-2):189-197.

41. Jagetia GC, Reddy TK (2011) Alleviation of iron induced oxidative stress by the grape fruit flavone naringin in vitro. Chem Biol Interact 190(2-3):121-128.

42. Adebiyi OA, Adebiyi OA, Owira PM (2015) Naringin reverses hypertensive cardiovascular disease in rats. J Nutr 140(1):44-48.

43. Turgut NH, Kara H, Elgoaz S, Devedik C, Gongor H, et al. (2016) The protective effect of naringin against bleomycin-induced pulmonary fibrosis in Wistar rats. Pulm Med 2016:760393.

44. Ma X, Lv J, Sun S, Ma J, Xing G, et al. (2016) Naringin ameliorates bone loss induced by sciatic neurectomy and increases Seraphin 3A expression in denervated bone. Sci Rep 6:24562.

45. Kumar A, Dogra S, Prakash A (2010) Protective effect of naringin, a citrus flavonoid, against colchicine-induced cognitive dysfunction and oxidative damage in rats. J Med Food 13(4):976-984.

46. Kim D, Lee SJ, Lee SB, Park K, Kim WJ, et al. (2008) Requirement for Ras/raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 29(9):1701-1709.

47. Sandermann H, Stromiger JL (1972) Purification and properties of C 55-isoprenoidalcohol phosphokinase from Staphylococcus aureus. J Biol Chem 247(16):5123-5131.

48. Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 582(1):67-78.

49. Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249(22):7130-7139.

50. Abei H (1984) Catalase in vitro. Methods Enzymol 105:121-126.

51. Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the auto oxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47(3):469-474.

52. Ohkawa ON, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):391-398.

53. Pendleton M, Lindsey RH Jr, Felix CA, Grimwade D, Oshenoff N (2014) Topoisomerase II and leukemia. Ann NY Acad Sci 1310:98-110.

54. Nitiss JL (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9(5):327-337.

55. Ichikawa Y, Ghanem A, Wu R, Khechaduri A, Naga Prasad SV, et al. (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124(2):617-630.

56. Minotti G, Menpa P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclics: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185-229.

57. McCord JM, Fridovich I (1969) Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244(22):6049-6055.

58. Lushchak VI (2012) Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids 2012:6049-6055.

59. Lu SC (2013) Glutathione synthesis. Biochim Biophys Acta 1830(5):3143-3153.

60. Schumacker PT (2015) Reactive oxygen species in cancer: A dance with the devil. Cancer Cell 27(2):156-157.

61. Todorova VK, Kaufmann Y, Hennings L, Klimberg VS (2010) Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr 140(1):44-48.

62. Jagetia GC, Venkatesh P (2015) An indigenous plant bael (Aegle marmelos (L.) Correa) extract protects against the doxorubicin-induced cardiotoxicity in mice. Biochem Physiol 4:3.

63. Jagetia GC, Lahnuntluangi V (2016) The citrus flavanone naringin enhances antioxidant status in the albino rat liver treated with doxorubicin. Biochem Mol Biol J 2:2.

64. Papasani VRM, Hanumantharayappa B, Annapurna A (2014) Cardioprotective effect of naringin against doxorubicin induced cardiomyopathy in rats. Indo American Journal of Pharmaceutical Research 4(5):2593-2598.

65. Kwatra M, Kumar V, Jangra A, Mishra M, Ahmed S, et al. (2016) Ameliorative effect of naringin against doxorubicin-induced acute cardiac toxicity in rats. Pharm Biol 54(4):637-647.

66. Fiser B, Jöjärt B, Csizmadia IG, Viskolcz B (2013) Glutathione-Hydroxyl radical interaction: A theoretical study on radical recognition process. PLoS ONE 8(9):e73652.

Citation: Jagetia GC, Lalrinenyi C (2017) Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice. Mol Anat Physiol 4(2):00130. DOI:10.15406/moajp.2017.04.00130
67. Laborde E (2010) Glutathione transferases as mediators of signalling pathways involved in cell proliferation and cell death. Cell Death Differ 17(9): 1373-1380.

68. Kodydková J, Vávrová I, Kocák M, Žák A (2014) Human catalase, its polymorphisms, regulation and changes of its Activity in different diseases. Folia Biol (Praha) 60(4): 153-167.

69. Soliman HA, Ahmed RR, Ali AT (2014) Assessment of the chemopreventive effects of various plant constituents against doxorubicin-induced toxicity in rats. J Am Sci 10: 153-164.

70. Perry JJ, Shin DS, Getzoff ED, Tainer JA (2010) The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta 1804(2): 245-262.

71. Yin H, Xu L, Porter NA (2011) Free radical lipid peroxidation: mechanisms and analysis. Chem Rev 111(10): 5944-5972.

72. Pieniążek A, Czapas J, Piaseczka Zelga J, Gwoździński K, Koceva Chyla (2013) Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Adv Med Sci 58(1): 104-111.

73. Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, et al. (2009) NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochim Biophys Res Commun 388(4): 727-731.

74. Li W, Wang C, Peng J, Liang J, Jin Y, et al. (2014) Naringin inhibits TNF-α induced oxidative stress and inflammatory response in HUVECs via Nox4/NF-κB and PI3K/Akt pathways. Curr Pharm Biotechnol 15(12): 1173-1182.

75. Jeon SM, Bok SH, Jang MK, Kim YH, Nam KT, et al. (2002) Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. Clin Chim Acta 317(1-2): 181-190.

76. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52(6): 1213-1225.

77. Li D, Li J, An Y, Yang Y, Zhang SQ (2013) Doxorubicin-induced apoptosis in H9c2 cardiomyocytes by NF-κB dependent PUMA upregulation. Eur Rev Med Pharmacol Sci 17(17): 2323-2329.

78. Zhang DX, Ma DY, Yao QZ, Fu CY, Shi YX, et al. (2016) ERK1/2/p53 and NF-κB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis. Eur Rev Med Pharmacol Sci 20(11): 2435-2442.

79. Liang J, Wang C, Peng J, Li W, Jin Y, et al. (2016) Naringin regulates cholesterol homeostasis and inhibits inflammation via modulating NF-κB and ERK signaling pathways in vitro. Pharmazie 71(2): 101-108.

80. Kulaeekaran G, Ganapasam S (2015) Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells. Mol Cell Biochem 409(1-2): 199-211.